GlassScriptPhysician profile
Amber Hunt
NPI 1578213344
$9,073.68
in general payments reported to CMS, 2019-2025
12 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $5,351 · 2023: $2,263 · 2024: $1,047 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,879 · Travel and Lodging: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,878.61 |
| Travel and Lodging | $843.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,570.81 | 2022-2025 | Synchromedii, Intellis Adaptivestim |
| Boston Scientific Corporation | $2,292.45 | 2022-2025 | Intracept, Wavewriter Alpha Prime 16, General - Pain Management |
| Bioventus LLC | $1,046.54 | 2023 | Stimrouter Implantable Kit |
| Spinal Simplicity, LLC | $988.36 | 2022 | |
| Nevro Corp. | $420.55 | 2022-2023 | Senza |
| Saluda Medical Americas, INC. | $303.41 | 2023-2024 | Evoke Scs, Evoke |
| Spr Therapeutics, INC | $240.05 | 2023-2024 | Sprint Pns System |
| Curonix LLC | $81.29 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Averitas Pharma INC. | $58.00 | 2023 | Qutenza |
| Relievant Medsystems, INC. | $40.97 | 2023 | Intracept |
| Tersera Therapeutics LLC | $18.61 | 2022 | |
| Vertos Medical, INC. | $12.64 | 2024 | Mild Device Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.